Margaret A.WinkerMD, Deputy EditorIndividualAuthorPhil B.FontanarosaMD, Interim CoeditorIndividualAuthor
Copyright 1999 American Medical Association. All Rights Reserved.
Applicable FARS/DFARS Restrictions Apply to Government Use.1999
To the Editor: Mr Brown and Dr Garber1 present an interesting model evaluating the cost-effectiveness
of new methods for improving cervical cancer screening. Principles of public
health practice suggest that the best screening programs are those involving
relatively common conditions that can have a significant impact on quality
of life and for which there are acceptable, available, and affordable tests
and treatments.2 New technologies claim
to enhance the sensitivity of the Papanicolaou (Pap) test and increase the
likelihood that a precancerous lesion will be detected in a single visit.
This is particularly important in high-risk underserved areas where annual
screening visits can be difficult to achieve.
Leidy NK, Brown R, Luce B, Sheets E. Cost-effectiveness of Methods to Enhance Sensitivity of Papanicolaou Testing. JAMA. 1999;282(15):1419-1420. doi:10.1001/jama.282.15.1419